Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

计划入组 12 人 · 首次发布于 2011 年 11 月 30 日

Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes

计划入组 100 人 · 首次发布于 2015 年 10 月 22 日

Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)

计划入组 24 人 · 首次发布于 2016 年 2 月 5 日

cancer therapeutics (evotec/Bristol-Myers Squibb)

neurodegenerative disease program (Evotec/Bristol-Myers Squibb)

Factor XIa inhibitor (BMS)

BRISTOL MYERS SQUIBB

United States

Bristol-Myers Squibb Company

United States

Bristol-Myers Squibb SA

Switzerland

Syngene International Extends Strategic Bristol Myers Squibb Collaboration Through 2035

EMA Validates Bristol Myers Squibb's Repotrectinib Application for ROS1-Positive and NTRK-Positive Tumors

Bristol Myers Squibb and Bain Capital Launch $300M Immunology Drug Development Venture